What is ADRx?
ADRx is at the forefront of drug discovery, specializing in the transformation of atomic structures into small molecule therapies designed to combat neurodegenerative diseases such as Alzheimer's, ALS, and Parkinson's Disease. The company leverages pioneering structure-based design methodologies to disrupt protein aggregation, a key mechanism in these debilitating conditions. By focusing on patient-derived pathological protein structures, ADRx aims to identify and develop groundbreaking therapeutics. Their innovative approach has already led to the discovery of novel small molecule modulators that effectively target pathological protein-protein interactions, including amyloids and biomolecular condensates. ADRx's client base includes researchers and healthcare providers dedicated to advancing treatments for neurodegenerative disorders.
How much funding has ADRx raised?
ADRx has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for ADRx?
With its substantial backing, ADRx is poised for significant expansion in its late-stage development efforts. The company's focus on structure-based design for neurodegenerative diseases positions it strategically within a critical area of unmet medical need. Future endeavors will likely involve advancing its pipeline of small molecule therapies through clinical trials, further validating its unique approach to disrupting protein aggregation. This capital infusion is expected to accelerate research and development, potentially leading to the commercialization of therapies that could transform patient outcomes in Alzheimer's, ALS, and Parkinson's disease.
See full ADRx company page
